Bromocriptine and Prostatic Carcinoma: Plasma Kinetics, production and Tissue Uptake of3H-Testosterone in Vivo
| Autor: | K. Sinterhauf, Jens E. Altwein, Günther H. Jacobi, K.H. Kurth |
|---|---|
| Rok vydání: | 1978 |
| Předmět: |
Male
medicine.medical_specialty Urology Endogeny In vivo Internal medicine medicine Carcinoma Humans Testosterone Bromocriptine Aged business.industry Biopsy Needle Prostatic Neoplasms Luteinizing Hormone medicine.disease Prolactin Kinetics Plasma kinetics Endocrinology Needle biopsy Follicle Stimulating Hormone business Hormone medicine.drug |
| Zdroj: | Journal of Urology. 119:240-243 |
| ISSN: | 1527-3792 0022-5347 |
| DOI: | 10.1016/s0022-5347(17)57445-5 |
| Popis: | The influence of the anti-prolactin bromocriptine on plasma kinetics, production rate and tissue uptake of testosterone was investigated in 15 patients with newly diagnosed stages C and D prostatic carcinoma. Bromocriptine was given for 5 days in a daily dose of 15 mg. orally. The studies were performed with the single injection technique using the 2-compartment model. Plasma testosterone, serum prolactin, and luteinizing and follicle-stimulating hormones were determined initially. Blood samples were drawn up to 5 hours after the injection of 3H-testosterone. For tissue studies a transrectal needle biopsy was done 3 hours post-injection. Bromocriptine suppressed prolactin and the endogenous testosterone level. Furthermore, it favored the elimination of 3H-testosterone, lowered the production rate of testosterone and hampered the in vivo uptake of the 3H-label into prostatic carcinoma tissue. Finally, the grading of the tumor lesions affected only the pre-bromocriptine uptake of radioactive androgens and not the uptake in response to bromocriptine. The potential clinical impliications of these observations are discussed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|